U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07193667) titled 'CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease' on Sept. 15.
Brief Summary: In this study, CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases. This study intends to use retroviral vector-based tandem CAR-T cells targeting CD19 to treat autoimmune disease. The CAR-T cells were provided by Shenzhen Cell Valley. A study published in the New England Journal of Medicine provides strong evidence for the therapeutic potential of CD19 CAR-T therapy in autoimmune diseases. The study enrolled 15 participants, including eight with severe SLE, three with idiopathic inflammatory myositis, ...